Page 29 - Bd Becton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article FRANKLIN LAKES, N.J., April 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrep ™ Hi-Lite Orange™ 26 mL Applicator (2% w/w chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) to the user level due to a defective applicator. The product is used as an antiseptic for the preparation of the patient's skin prior to surgery to help reduce bacteria that potentially can cause skin infection 1. BD ChloraPrep™ Hi-Lite Orange 26 mL A...

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular...

BD To Announce Financial Results For Its Second Quarter Of Fiscal 2021 News provided by Share this article Share this article FRANKLIN LAKES, N.J., April 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021. BD will issue a press release detailing the quarter's results, along with related presentation materials posted to www.bd.com/investors, at approximately 6:00 a.m. Eastern Time (ET). BD management will host a conference call and webcast at 8:00 a...

Share this article Share this article FRANKLIN LAKES, N.J., April 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its rapid antigen test to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals. BD today announced the FDA has granted Emergency Use Authorization (EUA) for its BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 to be used for SARS-CoV-2 screening through serial t...

Share this article Share this article TUCSON, Ariz., April 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company's supply chain, serving as a final-stage manufacturing and sterilization center.   The new 120,000 square-foot facility will be built on approximately 32 acres at the northeast corner of Valencia and Kolb Road and is planned to be operational in mid-2022.  BD plans to add approxima...